KRN2 bromide

KRN2 (bromide) is a selective inhibitor of nuclear factor of activated T cells (NFAT5) , with an IC 50 of 0.1 μM. In Vitro KRN2 selectively suppresses the expression of pro-inflammatory genes, including Nos2 and Il6, without hampering high-salt-induced NFAT5 and its target gene expressions. KRN2 dose-dependently inhibits the NF-κB p65 binding to Nfat5 promoter 1 and directly blocks the interaction between NF-κB p65 and its DNA binding sequence in the upstream site (base pairs -3000 to +1) of Nfat5 exon 1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo KRN2 (3 mg/kg, i.p., daily for 2 weeks) effectively suppresses AIA in which innate immune cells play a predominant role . KRN2 (3 mg/kg, i.p., daily) effectively suppresses CIA as well as AIA in mice, decreasing the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 8-week-old C57BL/6 mice injected intradermally with 2 mg of complete Freund's adjuvant . Dosage: 3 mg/kg. Administration: Peritoneally (i.p.) daily for 2 weeks. Result: Effective in suppressing AIA. Animal Model: 8-week-old DBA/1Jmice immunized with bovine type II collagen . Dosage: 3 mg/kg. Administration: Peritoneally (i.p.) daily. Result: Effective in suppressing CIA as well as AIA in mice, decreasing the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration. Form:Solid IC50& Target:IC50: 100 nM (NFAT5)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet